Synapse Open Synapse
Biology

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

BioPharma Dive · · 3 min read

The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R&D pacts.

Latest from BioPharma Dive